Access to Medicines: Antimalarials WHO/UNICEF Technical Briefing Seminar 10 October 2007 Silvia Schwarte Supply Chain Management Global Malaria Programme.

Slides:



Advertisements
Similar presentations
MATERIALS AND METHODS Leaves and roots of Moringa stenopetala were collected around Arbaminch town (Southern Ethiopia) in October The plant parts.
Advertisements

MDG Target 8.E gap analysis Ms. Alexandra Cameron Department of Essential Medicines and Pharmaceutical Policies, World Health Organization 27 August 2008.
Scaling Up Access and Rational Drug Use Anthony D. So, MD, MPA Program on Global Health and Technology Access Sanford School of Public Policy Duke University.
Student: Song Lijie Advisor: Prashant Yadav Santiago Kraiselburd
Private Sector Malaria Case Management: Experience from 7 years of implementation in Cambodia Presented by Dr. Socheat, Director of CNM RBM Working Group.
Global impact of medicine shortages Lisa Hedman World Health Organization Department of Essential Medicines and Health Products Toronto, Canada June.
WHO Training Course on Prequalification Introduction Efficacy and Safety Issues Hans Kemmler Consultant to WHO Accra, 5.Nov
Worldwide Antimalarial Resistance Network (WWARN) Centre for Tropical Medicine & Global Health University of Oxford APPMG meeting January 20 th, 2015.
ACCESS TO MEDICINES | 1 Access to Antimalaria Medicines: the Impact Malaria approach F. Bompart, M Bernhardt ICIUM 2011, Antalya, November 16, 2011 Session.
DEVELOPMENT IN THE PRODUCTION AND EFFECTIVENESS OF ARTEMISININ Background Information Currently, there is an epidemic of malaria in third world countries,
Challenges & responses for malaria in Asia
Global high-level subsidy for ACT procurement to facilitate low-cost commercial, & other, distribution (allowing effective, affordable home treatment or.
World Health Organization
Malaria medicines and diagnostics WHO/UNICEF TBS Access to medicines 19 November Geneva Silvia Schwarte Global Malaria Programme.
World Health Organization
Access to HIV/AIDS, Tuberculosis and Malaria Medicines. WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies. Geneva, 18 – 22 September.
Choice of antimalarial drugs Malaria Medicines & Supplies Services RBM Partnership Secretariat.
TBS Meeting Geneva, November 2011 Global Fund Policies and Reporting on Procurement of Health Products WHO/UNICEF Technical Briefing Seminar on Essential.
9/11 “The Malaria epidemic is like loading up seven Boeing 747 airplanes each day then deliberately crashing them into Mt Kilamanjaro” Chairman Malaria.
Essential Medicines Technical Briefing Seminar 1 |1 | Access to essential medicines for NCDs WHO EMP and NVI Departments Access to essential medicines.
The South African Malaria Initiative A Case Study E Jane Morris Bridging the Gap in Global Health Innovation - from Needs to.
Malaria Landscape 2007 Executive Director's Report to the 13 th Board Meeting.
1 |1 | Prequalification Programme – Stakeholders Meeting Geneva, February 2010 Access to Assured-Quality Praziquantel for the Control of Human Schistosomiasis.
Business environment for WHO prequalified medicines Arab Union of the Manufacturers of Pharmaceuticals and Medical Appliances Amman, Jordan, 13 June 2013.
Supply and quality of antimalarial medicines and diagnostics: introduction of issues Dr Andrea Bosman Global Malaria Programme Geneva, 9 July 2009 RBM.
Update on work on the Global ACT Subsidy Roll Back Malaria Global ACT Subsidy Task Force Presentation to RBM Board 10 May 2007.
Update and future directions for prequalification of medicines WHO HQ, Geneva, 4 February 2008 Dr Lembit Rägo Coordinator Quality Assurance and Safety:
Diagnostics and Medicines
MALARIA TRACK SESSION SUMMARIES_ICIUM 2011 TEAM MEMBERS: EVELYN ANSAH, KOJO YEBOAH-ANTWI, CHARLES EZENDUKA, DAVID OFORI-ADJEI.
Synthetically Engineered Artemisinin Lianne Ryan.
“The causes of Anti-TB medicines shortages in EMR countries and how to avoid them in the future” Khaled Sultan Drug Management Technical Officer, STOP.
BLI Research Project By: Tiffany Hou Artemisinin.
Malaria Case management KPA conference. Presentation outline  Introduction  National malaria strategy  Case management targets  AMFm subsidy  The.
Malaria treatment policies: the challenge, strategies and the options SOTA, Nairobi, Kenya 12 th June 2002.
Access to Artemisinin-Based Antimalarial Products Dr Clive O Ondari Essential Drugs and Medicines Policy Dept & Roll Back Malaria (RBM) Department World.
Issues in malaria diagnosis and treatment May 31, 2007 Jacek Skarbinski, MD Malaria Branch Centers for Disease Control and Prevention.
UNITAID Matching Innovation and Sustainability: An Innovative Mechanism for Scaling-up Treatment for HIV/AIDS, TB and Malaria Jorge Bermudez, Executive.
Quality Assurance for pharmaceutical products in international procurement Approach of major donors and procurers Core presentation prepared by Sophie.
TB Management: A Medical Aid Perspective presented by Dr Noluthando Nematswerani.
WHO/Roll Back Malaria – 3 May Forecast of ACT needs based on current and expected changes in antimalarial treatment policies Procurement, Quality.
Philippe Duneton11 February 2009 Deputy Executive Secretary 5th Consultative Stakeholder Meeting UN Prequalification of Diagnostics, Medicines & Vaccines.
1 Ensuring medicines save lives: Facilitating access Defeating Malaria Together Jaya Banerji Director, Communications & Advocacy MMV.
An update of artemisinin resistance and its containment efforts
MONITORING MEDICINE AVAILABILITY AND PRICES IN UGANDA By Denis Kibira HEPS Uganda.
TBS Meeting Geneva, November 2010 Procurement and Supply Management Policies WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies, November.
Key Issues from DAY 2 31 st January 2006 Jane Masiga & Val Remedios.
The WHO Prequalification of Medicines Program - Introduction Tony Gould Manager, Prequalification of Medicines Program WHO.
Pharmaceutical Working Group Working Group on Pharmaceuticals Key Points for Advocacy and Action.
Optimizing the Cost and Quality of HIV / AIDS Care and Treatment Anil Soni, Clinton HIV / AIDS Initiative 19 th Board Meeting, Geneva 6 May 2009.
1 |1 | Quality of Active Pharmaceutical Ingredients Beijing, 31 March 2010 Access to Assured-Quality Praziquantel for the Control of Human Schistosomiasis.
Points of Agreement Artemisinins should be the mainstay of first-line treatment in the short-to-medium term, at least First-line treatment for uncomplicated.
Update from GMP – Malaria Prevention, Diagnostics and Treatment Silvia Schwarte Prevention, Diagnostics and Treatment Interagency.
Seasonal Malaria Chemoprevention: WHO Policy and Perspectives
Access to Antimalarial Medicines EDM-RBM Collaboration
Table 1 Characteristics of patients at enrollment who received artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL) for treatment of malaria.
Malaria Medicines and Diagnostics
PSM Technical Briefing Seminar: Day One report
Global Drug Facility An innovative approach to supplying anti-TB drugs
Access to Medicines for HIV/AIDS, Tuberculosis and Malaria.
World Health Organization
Access to Antimalarial Medicines
Drug Management for Malaria within LSDI region
Access to Artemisinin-based Antimalarial Medicines
Comparison of current lowest global price vs estimated generic price, for medicines for diseases with large international treatment programmes. Comparison.
Drug Management for Malaria within LSDI region
Quality Problems with Antimalarials
WHO Global HIV/AIDS Staff Meeting
Novel Population-Level Malaria Treatment Strategies for the 2020s
An Enabling Business Environment and A Strategic Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,
An Enabling Business Environment and A Strategy and Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,
Presentation transcript:

Access to Medicines: Antimalarials WHO/UNICEF Technical Briefing Seminar 10 October 2007 Silvia Schwarte Supply Chain Management Global Malaria Programme

Access to Medicines: Antimalarials | 10 October | Malaria 107 countries: million episodes/year (Africa: 57% of all cases) Over-consumption of antimalarial drugs: 40-60% of all cases treated as malaria are febrile episodes Treatment availability: predominantly private sector (limited control with limited information on efficacy, safety and quality; use of mono- therapies, patient`s compliance, resistance) Disease of poverty: low market attraction for companies (many products instead of quality, lack of innovator products, stability, artemisinin-based mono-therapies)

Access to Medicines: Antimalarials | 10 October | WHO recommendations: ACTs WHO Guidelines for the Treatment of Malaria: AL, AS+AQ, AS+SP, AS+MQ National antimalarial medicines policy Risk of resistance (decreased in vitro sensitivity; in vivo: increased Parasite Clearance Time) Ban of oral artemisinin-based mono-therapies

Access to Medicines: Antimalarials | 10 October | (1.) National Medicines Policy and (2.) Procurement and Forecast of ACTs Millions of ACT treatment courses Cumulative No. of countries adopting ACT as 1st-line Rx Cumulative number of countriesadopting ACTs as1st-line treatment Cumulative number of countriesdeploying ACT s Forecast: 124 Million

Access to Medicines: Antimalarials | 10 October | ACT - market situation Fig. 1: Estimates of artemisinin dry leaves production (metric tonnes) Fig. 2: Artemisinin prices (USD/kg) over time

Access to Medicines: Antimalarials | 10 October | New ACTs on the market in New ACTs on the market in AS-MQ co-blistered products AS-AQ CD-AS (CDA) DHA-PPQ Paediatric Coartem™ Pyronaridine-AS Pyramax™ AS-Naphthoquine AS-Piperaquine < 2006 Fixed-dose combinations artemether- lumefantrine + Resistance

Access to Medicines: Antimalarials | 10 October | The way forward… New extraction processes New sources of artemisinin (e.g. biotechnology yeast cultures, high yield seeds) Mechanisms to avoid shortages and price fluctuation (safety stocks of artemisinin, predictable funding: AMFm, UNITAID) Pre-qualification: API and finished products Reliable forecasting: SCM-database

Access to Medicines: Antimalarials | 10 October | Thank you!

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.